Events & Press Releases
EMMAC presents to Scientific Committee (CSST) in Paris on Company’s advancement of scientific research into the therapeutic benefits of Medical Cannabis
16 May 2019, London. EMMAC Life Sciences Ltd, the European independent medical cannabis company, announces that on Wednesday 15th May, the Company presented to the French Scientific Committee (CSST),
Read more »
EMMAC to import cannabis products into Germany; supply agreement with CC Pharma
14 May 2019, London. EMMAC Life Sciences Ltd, the European independent medical cannabis company, announces that it has entered the German medical cannabis market through the incorporation of About
Read more »
Acquisition of Rokshaw, a leading UK Specials manufacturer
Immediate access to UK medical cannabis market 9 April 2019, London. EMMAC Life Sciences Ltd, the European independent medical cannabis company, is pleased to announce completion of the acquisition
Read more »
Medalchemy, EMMAC’s Spanish GMP certified laboratory, secures approval to import medical cannabis for scientific research
19 March 2019, London: EMMAC, the European independent medical cannabis company, is pleased to announce that Medalchemy, EMMAC’s fully-licensed GMP certified laboratory in Alicante, Spain, has secured approval from
Read more »
£11 million raised via successful Private Placing
‘Oversubscribed placing with institutional investment from across Europe, North America, Asia and Australia’ 8 March 2019, London. EMMAC Life Sciences Limited, the European independent medical cannabis company, is pleased
Read more »
EMMAC to present preliminary work on clinical trial design at 5th International Emerald Conference
EMMAC is pleased to announce that the Company will be presenting collaborative work with Imperial College at the 5th International Emerald Conference in San Diego on the 28th of February.
Read more »
EMMAC Announces Turnkey GMP Facility in Malta to be Group Import and Distribution Hub
EMMAC granted a Letter of Intent under terms of the Production of Cannabis for Medicinal Use Act 2018 EMMAC, the European independent medical cannabis company, is pleased to announce
Read more »
Announcing the acquisition of leading Swiss wellness CBD company Blossom
Emmac Life Sciences (“EMMAC” or the “Company”) is pleased to announce the acquisition of Blossom, a market-leading Swiss wellness CBD company. The acquisition provides EMMAC with a revenue-making portfolio
Read more »
Acquisition of a majority interest in Medalchemy, a GMP certified laboratory, in Alicante Spain
Medalchemy, a technology-based manufacturing company located on the premises of the University of Alicante, has more than a decade of experience in the research, development and manufacture of active pharmaceutical ingredients (APIs) and has submitted license applications to import, research, manufacture and export medical cannabis.
Read more »
Board and Leadership Appointments
Dr Barbara Pacchetti as Chief Scientific Officer and Dr Mikael Sodergren as Research Director Recognised scientific pioneers to drive research and innovation to shape the global future of medicinal
Read more »
Research collaboration with Imperial College London
A pre-clinical and clinical research programme to investigate cannabis-based medicinal products aimed to directly benefit patients. EMMAC, the European independent medical cannabis company, is pleased to announce a research
Read more »